
Experience
VectivBio to be Acquired by Ironwood
May 23, 2023
Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion.
Related contacts
Related Practices & Industries
Redx Pharma to Merge With Jounce Therapeutics
March 6, 2023
Cooley advised Redx Pharma, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a $425 million and contingent value right transaction.
Related contacts
Biote Agrees to Combine With SPAC Haymaker Acquisition Corp. III
December 16, 2021
Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.
Related contacts
Related Practices & Industries
Alvotech Agrees to Merge With SPAC Oaktree Acquisition Corp. II
December 9, 2021
Cooley advised Alvotech Holdings, a global biopharmaceutical company focused on the development and manufacturing of biosimilar medicines for patients worldwide, on its agreement to merge with special purpose acquisition company (SPAC) Oaktree Acquisition Corp. II. Lawyers Michal Berkner, Div Gupta, Nicolas Dumont and Jarrett Burks led the Cooley team advising Alvotech.
Related contacts
Related Practices & Industries
ZOLL Medical Agrees to Acquire Itamar Medical for $538 Million
September 21, 2021
Cooley advised ZOLL Medical, a company that manufactures medical devices and related software solutions, on its definitive agreement to acquire publicly traded medical technology company Itamar Medical. Lawyers Michal Berkner, Lester Fagen, Michael McGrail, Jarrett Burks and Vlad Herta led the Cooley team advising ZOLL Medical.